Short Interest in IO Biotech, Inc. (NASDAQ:IOBT) Declines By 9.4%

IO Biotech, Inc. (NASDAQ:IOBT - Get Free Report) saw a significant decline in short interest in the month of April. As of April 15th, there was short interest totalling 61,800 shares, a decline of 9.4% from the March 31st total of 68,200 shares. Approximately 0.2% of the shares of the company are sold short. Based on an average daily trading volume, of 133,900 shares, the short-interest ratio is presently 0.5 days.

IO Biotech Trading Up 4.9 %

Shares of NASDAQ:IOBT traded up $0.07 during trading on Monday, reaching $1.49. The company had a trading volume of 46,365 shares, compared to its average volume of 128,780. IO Biotech has a fifty-two week low of $0.82 and a fifty-two week high of $2.64. The stock's fifty day moving average price is $1.61 and its 200 day moving average price is $1.49.

IO Biotech (NASDAQ:IOBT - Get Free Report) last posted its quarterly earnings results on Tuesday, March 5th. The company reported ($0.40) earnings per share for the quarter, missing analysts' consensus estimates of ($0.36) by ($0.04). Equities analysts anticipate that IO Biotech will post -1.41 EPS for the current year.

Insiders Place Their Bets

In other IO Biotech news, major shareholder Holdings A/S Novo sold 658,809 shares of IO Biotech stock in a transaction that occurred on Friday, February 9th. The stock was sold at an average price of $1.50, for a total transaction of $988,213.50. Following the transaction, the insider now owns 5,088,258 shares of the company's stock, valued at $7,632,387. The transaction was disclosed in a filing with the SEC, which is available at this link. 3.50% of the stock is currently owned by corporate insiders.

Institutional Trading of IO Biotech

A number of institutional investors have recently modified their holdings of IOBT. Armistice Capital LLC purchased a new stake in IO Biotech during the third quarter worth $3,029,000. Vivo Capital LLC boosted its position in IO Biotech by 104.7% during the third quarter. Vivo Capital LLC now owns 6,173,439 shares of the company's stock worth $8,705,000 after purchasing an additional 3,157,894 shares in the last quarter. Stonepine Capital Management LLC purchased a new stake in IO Biotech during the third quarter worth $2,785,000. Finally, PFM Health Sciences LP boosted its position in IO Biotech by 73.0% during the fourth quarter. PFM Health Sciences LP now owns 2,341,107 shares of the company's stock worth $4,401,000 after purchasing an additional 987,654 shares in the last quarter. 54.76% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reissued a "buy" rating and issued a $8.00 target price on shares of IO Biotech in a report on Wednesday, March 6th.

About IO Biotech

IO Biotech, Inc, a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive mechanisms mediated by Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to treat lung, head and neck, bladder, and melanoma cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.